Figures for:
Pandrug-Resistant Acinetobacter baumannii Causing Nosocomial Infections in a University Hospital, Taiwan

[Emerg Infect Dis 8(8), 2002. © 2002 Centers for Disease Control and Prevention (CDC)]

Figure 1. Annual consumption (gram/patient-day x 1,000) of carbapenems (imipenem and meropenem), extended-spectrum cephalosporins (cefotaxime, ceftroaxone, ceftazidime, and cefepime), ciprofloxacin, aminoglycosides (gentamicin, tobramycin, netilmicin, and amikacin) and percent of isolates of imipenem-resistant and pandrug-resistant Acinetobacter baumannii (PDRAB) at the National Taiwan University Hospital, 1993-2000.

Figure 2. (A) Ten pulsotypes obtained by pulsed-field gel electrophoresis (PFGE) after digestion with SmaI. Lane M, molecular size marker. Lanes A to J, pandrug-resistant Acinetobacter baumannii (PDRAB) isolates belonging to pulsotypes A to J, respectively. (B) Ten subtypes of pulsotype E. Lanes M, molecular size marker. Lane E1 to E10, PDRAB isolates belonging to subtypes E1 to E10, respectively.

Figure 3. Random amplified polymorphic DNA (RAPD) patterns generated by arbitrarily primed polymerase chain reaction for pandrug-resistant Acinetobacter baumannii (PDRAB) isolates using two primers OPA-05 (A) and OPA-02 (B). Lane M, molecular size marker. Lanes A to J, RAPD patterns 1 to 10. Isolates of PDRAB belonging to pulsotypes A to J exhibit RAPD pattern 1-10, respectively.

Figure 4. (A) Distribution of pulsed-field gel electrophoresis (PFGE) profiles (pulsotypes) of pandrug-resistant Acinetobacter baumannii (PDRAB) isolates, May 1998-April 2000. Number within each bar indicates number of isolates with pulsotype E (clone 5). Letter above indicated bar denotes isolates exhibiting pulsotype(s) other than pulsotype E. (B) Distribution of pulsotype E in seven intensive-care units (ICU-1 to ICU-7) and 13 general wards (GW). Number above each bar indicates number of isolates with pulsosubtype E2.